SCHEMBL1507914

SCHEMBL1507914

CC(C)C(C#N)(c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP17A1 P05093 1/20 0.35
KCNN4 O15554 1/20 0.33
ACHE P22303 1/20 0.33
AR P10275 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.32
USP2 O75604 1/20 0.32
CTSL P07711 4/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
ALDH1A1 P00352 2/20 0.32
LMNA P02545 2/20 0.32
ALPG P10696 1/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
XBP1 P17861 1/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1508074 0.86 KCNN4 (0.43) CYP3A4CYP2D6CYP17A1KCNN4ACHE
SCHEMBL1508072 0.82 KCNN4 (0.43) CYP3A4CYP2D6KCNN4ARNPC1
SCHEMBL10346447 0.79 CYP2D6 (0.71) CYP3A4CYP2D6ALDH1A1LMNAMAPT
SCHEMBL1507923 0.75 HTT (0.41) CYP3A4CYP2D6KCNN4NPC1RAB9A
SCHEMBL10157191 0.75 RAB9A (0.38) CYP3A4CYP17A1KCNN4ACHENPC1
SCHEMBL2534039 0.73 RAB9A (0.37) CYP17A1KCNN4ACHENPC1RAB9A
SCHEMBL1508141 0.72 CYP2D6 (0.42) CYP3A4CYP2D6ARCTSLALDH1A1
SCHEMBL17451561 0.71 RAB9A (0.36) CYP17A1KCNN4ACHENPC1RAB9A
SCHEMBL18016870 0.71 ESR1 (0.41) CYP17A1ARNPC1RAB9AUSP2
SCHEMBL24278470 0.70 RAB9A (0.38) CYP3A4CYP17A1KCNN4ACHENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1465863-B1 POTASSIUM CHANNEL MODULATORS NEUROSEARCH AS (DK) 2008-07-09 EP claimed
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP claimed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US claimed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US claimed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US claimed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP claimed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO claimed
EP-1911740-B1 POTASSIUM CHANNEL MODULATORS NEUROSEARCH AS (DK) 2013-02-27 EP disclosed
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
EP-1465863-B1 POTASSIUM CHANNEL MODULATORS NEUROSEARCH AS (DK) 2008-07-09 EP disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US disclosed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP disclosed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009816-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 CYP3A4 2918/4885CYP2D6 2770/4885CYP17A1 3841/4885
US-20070161607-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 CYP3A4 2918/4885CYP2D6 2770/4885CYP17A1 3841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.